IDO1 and ovarian cancer: There is evidence that in ovarian cancer, the enzyme indoleamine 2,3-dioxygenase (IDO) catalyzes the breakdown of tryptophan through the kynurenine pathway, resulting in immunosuppressive compounds that accelerate the growth of tumor cells and reduce antitumor immunity (109, 110).